Skip to main content
. 2020 Nov 6;12:11411–11419. doi: 10.2147/CMAR.S260825

Table 1.

Relationship Between TF-PDC and Clinicopathological Features of AML Patients

Prognostic Variables No. TF-PDC
Negative Positive P-value
Gender
 Female 66 38 28 X2= 0.906 0.341
 Male 97 63 34
Age
 >46 85 54 31 X2= 0.185 0.667
 ≤46 78 47 31
FAB classification
 M4 80 53 27 X2= 1.225 0.268
 M5 83 48 35
ELN risk classification
 Favorable 63 35 28 X2= 7.228 0.027
 Intermediate 49 38 11
 Poor 51 28 23
Cytogenetics abnormality
 Favorable 42 26 16 X2= 1.294 0.523
 Intermediate 71 47 24
 Poor 50 28 22
Gene mutation
 NPM1 19 13 6 X2=0.381 0.537
 Flt3-ITD 24 9 15 X2=7.416 0.008
No. of chemotherapy before CR 1.93 (1–3) 2.9 (1–4) t=5.19 0.00
Median WBC (x109, range) 55.6 (0.87–307) 51.1 (1.8–474) t=5.18 0.00
Median Hb concentration (g/dL, range) 80.8 (47–151) 81.8 (38–135) t=6.88 0.00
Median platelet count (x109, range) 79.2 (9–381) 76.4 (8–258) t=3.61 0.00
Bone marrow blast (%, range) 59.7 (21–98.7) 68.4 (20–94) t=32.03 0.00